AveXis, Inc. (AVXS) Can’t Be More Safe. Trades Significantly Higher

December 7, 2017 - By Darrin Black

The stock of AveXis, Inc. (NASDAQ:AVXS) is a huge mover today! The stock increased 7.32% or $6.73 during the last trading session, reaching $98.7. About 449,817 shares traded or 26.32% up from the average. AveXis, Inc. (NASDAQ:AVXS) has risen 95.85% since December 7, 2016 and is uptrending. It has outperformed by 79.15% the S&P500.
The move comes after 8 months positive chart setup for the $3.16B company. It was reported on Dec, 7 by Barchart.com. We have $102.65 PT which if reached, will make NASDAQ:AVXS worth $126.24 million more.

Analysts await AveXis, Inc. (NASDAQ:AVXS) to report earnings on March, 15. They expect $-1.21 EPS, down 31.52 % or $0.29 from last year’s $-0.92 per share. After $-1.52 actual EPS reported by AveXis, Inc. for the previous quarter, Wall Street now forecasts -20.39 % EPS growth.

AveXis, Inc. (NASDAQ:AVXS) Ratings Coverage

Among 4 analysts covering AveXis (NASDAQ:AVXS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. AveXis had 5 analyst reports since May 13, 2016 according to SRatingsIntel. The firm has “Market Perform” rating given on Friday, July 15 by Wells Fargo. Bank of America initiated the stock with “Buy” rating in Friday, October 21 report. Jefferies maintained it with “Buy” rating and $50 target in Monday, September 19 report. The rating was upgraded by Jefferies to “Buy” on Friday, August 12. Goldman Sachs maintained the stock with “Buy” rating in Friday, May 13 report.

More notable recent AveXis, Inc. (NASDAQ:AVXS) news were published by: Fool.com which released: “AveXis Inc.: Buy at the High?” on July 18, 2017, also Globenewswire.com with their article: “AveXis Announces Plan to Initiate Pivotal Trial of AVXS-101 in SMA Type 1 …” published on September 29, 2017, Globenewswire.com published: “AveXis Reports Third Quarter 2017 Financial and Operating Results” on November 09, 2017. More interesting news about AveXis, Inc. (NASDAQ:AVXS) were released by: Nasdaq.com and their article: “Why AveXis (AVXS) Could Be Positioned for a Slump” published on December 06, 2017 as well as Reuters.com‘s news article titled: “BRIEF-Avexis Inc CFO Thomas Dee resigns” with publication date: October 19, 2017.

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company has market cap of $3.16 billion. The Company’s initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. It currently has negative earnings. The firm also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.